SCHEMBL25859548

SCHEMBL25859548

C=C(NC1COC1)c1ccn(C(C)C)n1

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.37
BRD4 O60885 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20759134 0.66 DYRK1A (0.33) KDM5A
SCHEMBL10026473 0.63 MME (0.39) KDM5A
SCHEMBL1431340 0.63 KMT2A (0.44) KDM5A
SCHEMBL19539129 0.63 BRD4 (0.42) KDM5ABRD4
SCHEMBL25332845 0.62 MEN1 (0.41) KDM5A
SCHEMBL19531884 0.62 KDM5A (0.41) KDM5A
SCHEMBL19282528 0.61 DRD4 (0.47) KDM5A
SCHEMBL19282527 0.61 DRD4 (0.47) KDM5A
SCHEMBL19294715 0.61 DRD4 (0.47) KDM5A
SCHEMBL22162567 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227470-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER VANDERBILT UNIVERSITY 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227470-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER KRAS, NRAS, TP53 KDM5A 3020/4885BRD4 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.